Ilaris (Canakinumab) in the Schnitzler Syndrome

NCT01245127 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Schnitzler Syndrome

Interventions

DRUG: Ilaris

Sponsor

Universitaire Ziekenhuizen KU Leuven